Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19858Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Sioka, C. | en |
| dc.contributor.author | Kyritsis, A. P. | en |
| dc.contributor.author | Fotopoulos, A. | en |
| dc.date.accessioned | 2015-11-24T19:03:00Z | - |
| dc.date.available | 2015-11-24T19:03:00Z | - |
| dc.identifier.issn | 1878-5883 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19858 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adrenal Cortex Hormones/adverse effects | en |
| dc.subject | Animals | en |
| dc.subject | Bone and Bones/metabolism/physiopathology | en |
| dc.subject | Comorbidity | en |
| dc.subject | Female | en |
| dc.subject | Genetic Predisposition to Disease/genetics | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Multiple Sclerosis/*epidemiology/genetics/metabolism | en |
| dc.subject | Osteoporosis/*epidemiology/genetics/metabolism | en |
| dc.subject | Receptors, Calcitriol/genetics | en |
| dc.subject | Vitamin D/metabolism/therapeutic use | en |
| dc.subject | Vitamin D Deficiency/*epidemiology/genetics/metabolism | en |
| dc.title | Multiple sclerosis, osteoporosis, and vitamin D | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1016/j.jns.2009.09.012 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/19800081 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0022510X09008545/1-s2.0-S0022510X09008545-main.pdf?_tid=b4c05bb9960b4000da79ddc9a50d2b3a&acdnat=1332859900_58203cc616cfc3fc26797ed1f1592993 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2009 | - |
| heal.abstract | Multiple sclerosis (MS) is associated with reduced bone mass and higher frequency of osteoporosis. Although high-dose short-term intravenous glucocorticoid regimens cause a decrease in bone formation, this effect is usually reversible and osteoporosis in MS patients may be independent of the short-term corticosteroid treatment. Clinical evidence suggests an important role of vitamin D as a modifiable risk factor in MS. Low circulating levels of vitamin D have been found in MS patients, especially during relapses, suggesting that vitamin D could be involved in the regulation of the clinical disease activity. Vitamin D mediates its function through a single vitamin D receptor (VDR). Polymorphisms of the VDR have major effects on vitamin D function and metabolism, and some VDR genotypes have been linked to osteoporosis and MS. Because the safety of high doses of vitamin D has not been established yet, vitamin D hasn't been used in enough doses to increase the serum level to a desired therapeutic target. Future clinical trials should determine the upper limit of vitamin D intake in order to achieve therapeutic benefit in MS patients. | en |
| heal.journalName | J Neurol Sci | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Sioka-2009-Multiple sclerosis.pdf | 190.04 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
